Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - interferon gamma-1b -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

clinigen healthcare ltd - aldesleukin - powder for solution for injection - 18mega unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd - urokinase - powder for solution for injection - 100000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd - urokinase - powder for solution for injection - 25000unit

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

syner-med (pharmaceutical products) ltd - urokinase - powder for solution for injection - 10000unit

Australia - English - Department of Health (Therapeutic Goods Administration)

beigene aus pty ltd - zanubrutinib, quantity: 80 mg - capsule - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; sodium lauryl sulfate; magnesium stearate; gelatin; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - waldenstr?m?s macroglobulinaemia (wm),brukinsa is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll),brukinsa is indicated as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), including patients with deletion 17p and/or tp53 mutation. mantle cell lymphoma (mcl),brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.,this indication was approved via the provisional approval pathway, based on objective response rate. continued approval for this indication depends on verification and description of clinical benefit in the confirmatory trials.,marginal zone lymphoma (mzl),brukinsa is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one-prior anti-cd20-based therapy.,this indication was approved via the provisional approval pathway, based on objective response rate. continued approval for this indication depends on verification and description of clinical benefit in the confirmatory trials.

Australia - English - Department of Health (Therapeutic Goods Administration)

medical & optical instruments australia pty ltd - 12253 - skin grafting knife - a reusable surgical instrument used to cut skin strips at the donor site that are intended for grafting

Australia - English - Department of Health (Therapeutic Goods Administration)

bosco medical australia - 46206 - skin moisturizing/barrier dressing - intended to provide an effective barrier to protect against skin irritation and damage from bodily fluids, wound fluids, adhesive products, and friction

Australia - English - Department of Health (Therapeutic Goods Administration)

bosco medical australia - 46206 - skin moisturizing/barrier dressing - intended to provide the skin with an effective moisturiser and long-term protection from bodily fluids

Australia - English - Department of Health (Therapeutic Goods Administration)

convatec australia pty ltd - 46206 - skin moisturizing/barrier dressing - non-sterile liquid preparation placed on the skin to protect the skin from the damaging effects of body waste, enzymes and adhesives. available as an aerosol and impregnated wipe.